Skip to content

• Company
  • About AGP
  • Vision & Mission
  • Detail of Associated Concerns
  • Leadership Team
  • History Timeline
• Governance
  • Auditors, Advisors ,Share Registrar and Bankers
  • Election of Directors
  • Board and its Committees
  • Share Holding Pattern
  • Key Elements of Significant Policies
• Investor Relations
  • Investor Information
    • Financial Statements
    • Code of Conduct
    • Financial Highlights
    • Latest EPS, P/E Ratio, and Break-up value of share
    • Free Float
    • Scrutinizer Report
    • List of Unpaid/Unclaimed Shares & Dividend
    • Name & Address of share registrar
    • PSX symbol and link, Rating
    • Gender Pay Gap Statement
  • Investor Contacts
  • Notices & Forms
  • Corporate Social Responsibility
  • Corporate Briefing Session
• Media
  • Certifications & Awards
  • Documentary
  • Events Gallery
  • Announcements/Clarifications
  • Website Compliance Certificate
• Business Partners
  • Distribution Channel
  • Export
  • Partnerships
• Products
  • Product List
  • Product Quality Management
  • Product Safety
• Careers
  • Why AGP
  • Job Openings

• English
  • اردو

Home > Generics > Sofosbuvir

Sofosbuvir

MyHep All

MyHep All is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection.

MyHep

MyHep (Sofosbuvir) is a nucleotide analog inhibitor of HCV NS5B polymerase. MyHep is a direct-acting antiviral agent against the hepatitis C virus